India Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Dermatophytosis, Mucormycosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Parenteral, Topical, Oral, Others), By End-User (Homecare, Hospitals, Clinics, Others), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

India Anti-Fungal Drugs Market was valued at USD 11263.10 Million in 2024 and is anticipated to reach USD 15130.62 Million by 2030, with a CAGR of 6.29% during 2025-2030.  

Anti fungal drugs treat infections in humans, animals, and plants, and are available as oral tablets, topical creams, and intravenous injections. These medicines target fungal cell walls, membranes, or key enzymes, stopping growth while limiting harm to human cells.

They address conditions ranging from mild skin infections such as athlete’s foot and thrush to severe systemic diseases like candidiasis and aspergillosis. Rising immunocompromised populations are increasing treatment need. 

Research has introduced new drug classes and combination therapies, expanding clinical options. Government programs aimed at strengthening public healthcare systems and improving access to essential medicines have supported wider availability and affordability, sustaining growth across the forecast period.

Key Market Drivers

Advancements in Anti-Fungal Drugs

• Advancements in anti-fungal drugs are strengthening the India anti-fungal drugs market by expanding therapeutic options, improving route flexibility, and enabling more precise management of invasive and resistant fungal infections in hospital settings. This is especially important as clinicians increasingly need effective therapies for high-risk and critically ill patients.

• Newer systemic anti-fungal therapies are gaining stronger clinical acceptance because physicians are increasingly favoring agents with better efficacy and safety profiles in difficult infections such as invasive candidiasis and mucormycosis. This shift is also improving confidence in treatment decisions across intensive care units, transplant settings, and complex inpatient care environments.

• Better pharmacokinetic understanding, greater use of intravenous-to-oral step-down strategies, and growing comfort with targeted treatment protocols are further supporting the use of advanced anti-fungal drugs in India. These developments are helping infectious disease specialists and intensivists move toward more evidence-based, individualized, and stewardship-aligned treatment approaches in severe fungal disease management.

• India’s role in anti-fungal innovation is also growing as global clinical development programs increasingly include Indian sites, giving local physicians earlier exposure to next-generation therapies and updated evidence-based care models. For instance, a multicenter Indian retrospective study across 127 centers and 323 patients found that posaconazole accounted for 38.6 percent of systemic antifungal prescriptions and anidulafungin for 32.8 percent, showing strong clinician preference for newer advanced therapies.

Growing Research and Development

• Growing research and development activity is reinforcing the India anti-fungal drugs market by improving drug availability, strengthening resistance surveillance, and accelerating validation of newer therapies for difficult-to-treat fungal diseases. This broader innovation focus is helping the market respond more effectively to both endemic fungal burdens and severe hospital-acquired infections.

• The market is benefiting from R&D efforts spanning complex injectable formulations, better fungal diagnostics, optimized dosing approaches, and stronger evidence generation around resistant pathogens such as Candida auris and invasive molds. These advances are making anti-fungal treatment more data-driven and clinically dependable in settings where rapid and accurate intervention is essential.

• India is also building stronger institutional capacity for fungal disease monitoring through national diagnostic and referral networks, which helps align research priorities with real-world treatment gaps seen in hospitals and intensive care units. This improves the relevance of innovation by linking development activity to actual clinical demand patterns and resistance challenges in the country.

• Regulatory and manufacturing responses during fungal emergencies have further shown that domestic capability can be scaled quickly when treatment demand becomes urgent. This strengthens confidence in India’s ability to support higher-value anti-fungal therapy segments through local development and supply. For instance, Biocon received US FDA approval on June 3, 2024, for Micafungin 50" mg"  and 100" mg"  vials, underscoring how India-linked R&D is moving into advanced systemic anti-fungal therapies.

Download Free Sample Report

Key Market Challenges

High treatment cost

• High treatment cost remains a major restraint on the India anti-fungal drugs market because severe fungal infections often require prolonged therapy, hospitalization, repeated dosing, diagnostics, and close monitoring, all of which substantially increase the total cost of care. This makes treatment financially burdensome even before complications or longer inpatient stays are considered.

• The affordability challenge is especially serious in urgent conditions such as invasive candidiasis, aspergillosis, and mucormycosis, where physicians cannot delay therapy while patients evaluate cheaper options or arrange financing. Even when lower-cost domestic formulations are available, the overall treatment journey can still be financially exhausting for households with limited insurance coverage or poor access to subsidized tertiary care.

• Cost pressure can directly affect treatment behavior by causing delayed initiation, incomplete therapy, or substitution toward less optimal antifungal regimens, which may weaken outcomes and reduce uptake of advanced therapies. This challenge extends beyond product pricing and reflects the combined economics of medicines, diagnostics, inpatient care, and follow-up management. For instance, an Indian postmarketing study on liposomal amphotericin B reported acquisition costs of about "Rs " 4,500 to "Rs " 8,000 per day and roughly "Rs " 0.9 lakh to "Rs " 2.1 lakh per treatment course.

Antifungal Resistance

• Antifungal resistance is becoming a serious barrier in the India anti-fungal drugs market because it reduces the reliability of standard therapies, complicates empirical prescribing, and increases the risk of prolonged or failed treatment in vulnerable patients. This makes fungal infection management more uncertain, especially where rapid and predictable response is clinically critical.

• As resistance rises across Candida species and other fungal pathogens, physicians are increasingly forced to depend on stronger diagnostics, longer treatment durations, and more expensive second-line or combination regimens. This raises both the clinical complexity and the economic burden of treatment, particularly in hospitals and intensive care units treating immunocompromised or critically ill patients.

• Resistance is also placing greater pressure on antifungal stewardship and product development because drug choice must now be guided more by species identification and susceptibility testing than by routine familiarity with older therapies. This turns resistance into not just a microbiological issue but also a commercial and operational challenge that can weaken confidence in existing regimens. For instance, a systematic review covering 106 Indian studies found antifungal resistance rates of 47.16 percent in Candida haemulonii, 28.99 percent in Candida krusei, 20.69 percent in Candida glabrata, and 10.34 percent even in Candida albicans isolates.

Key Market Trends

High treatment cost

• High treatment cost remains a major restraint on the India anti-fungal drugs market because severe fungal infections often require prolonged therapy, hospitalization, repeated dosing, diagnostics, and close monitoring, all of which substantially increase the total cost of care. This makes treatment financially burdensome even before complications or longer inpatient stays are considered.

• The affordability challenge is especially serious in urgent conditions such as invasive candidiasis, aspergillosis, and mucormycosis, where physicians cannot delay therapy while patients evaluate cheaper options or arrange financing. Even when lower-cost domestic formulations are available, the overall treatment journey can still be financially exhausting for households with limited insurance coverage or poor access to subsidized tertiary care.

• Cost pressure can directly affect treatment behavior by causing delayed initiation, incomplete therapy, or substitution toward less optimal antifungal regimens, which may weaken outcomes and reduce uptake of advanced therapies. This challenge extends beyond product pricing and reflects the combined economics of medicines, diagnostics, inpatient care, and follow-up management. For instance, an Indian postmarketing study on liposomal amphotericin B reported acquisition costs of about "Rs " 4,500 to "Rs " 8,000 per day and roughly "Rs " 0.9 lakh to "Rs " 2.1 lakh per treatment course.

Antifungal Resistance

• Antifungal resistance is becoming a serious barrier in the India anti-fungal drugs market because it reduces the reliability of standard therapies, complicates empirical prescribing, and increases the risk of prolonged or failed treatment in vulnerable patients. This makes fungal infection management more uncertain, especially where rapid and predictable response is clinically critical.

• As resistance rises across Candida species and other fungal pathogens, physicians are increasingly forced to depend on stronger diagnostics, longer treatment durations, and more expensive second-line or combination regimens. This raises both the clinical complexity and the economic burden of treatment, particularly in hospitals and intensive care units treating immunocompromised or critically ill patients.

• Resistance is also placing greater pressure on antifungal stewardship and product development because drug choice must now be guided more by species identification and susceptibility testing than by routine familiarity with older therapies. This turns resistance into not just a microbiological issue but also a commercial and operational challenge that can weaken confidence in existing regimens. For instance, a systematic review covering 106 Indian studies found antifungal resistance rates of 47.16 percent in Candida haemulonii, 28.99 percent in Candida krusei, 20.69 percent in Candida glabrata, and 10.34 percent even in Candida albicans isolates.

Segmental Insights

Drug Class Insights

• In 2024, the India Anti-Fungal Drugs Market largest share was held by Echinocandins drug class segment. Echinocandins are a class of antifungal drugs known for their effectiveness against invasive fungal infections, particularly those caused by Candida and Aspergillus species. These infections are common and can be life-threatening, which drives the demand for antifungal drugs from the Echinocandins class.

• Echinocandins have broad-spectrum antifungal activity, making them effective against a range of fungal pathogens. This versatility is a key factor in their prominence in the market. Echinocandins are generally well-tolerated by patients, and they have a favourable safety profile compared to some other antifungal drug classes. This makes them a preferred choice for healthcare providers when treating serious fungal infections.  

• In India Anti-Fungal Drugs market, the Azoles segment is anticipated to be dominating in the forecast period. Their broad-spectrum activity renders them effective against a wide range of fungal species, including both superficial and systemic infections. This versatility makes them indispensable in the treatment of conditions ranging from superficial skin infections to life-threatening systemic mycoses. Additionally, their relatively favorable safety profiles and ease of administration contribute to their widespread adoption in clinical practice.

• The rise in the incidence of fungal infections in India, driven by factors such as increasing immunocompromised populations, widespread antifungal resistance, and a surge in invasive procedures, underscores the need for potent antifungal agents like Azoles. The pharmaceutical industry's response to this demand has been significant, with continuous research and development efforts aimed at refining existing Azole formulations and developing novel agents with enhanced efficacy and safety profiles.

Indication Insights

• In 2024, the largest share of the India Anti-Fungal Drugs Market was held by the Aspergillosis segment and is predicted to continue expanding over the coming years.  Aspergillosis is a fungal infection caused by the Aspergillus species, and it is known to be one of the more common and clinically significant fungal infections in India. The prevalence of Aspergillosis is relatively high, particularly in patients with compromised immune systems, such as those with HIV/AIDS, organ transplants, or underlying respiratory conditions.

• This high prevalence drives the demand for antifungal drugs to treat Aspergillosis. Aspergillosis can manifest in various forms, including invasive aspergillosis, allergic bronchopulmonary aspergillosis (ABPA), and chronic pulmonary aspergillosis (CPA). Invasive aspergillosis is a severe and often life-threatening condition that requires aggressive antifungal treatment. As a result, the demand for antifungal drugs is higher for this condition. Aspergillosis requires specialized and targeted antifungal treatment, often with drugs such as voriconazole or isavuconazole. The complexity of treating Aspergillosis means that patients often seek care at specialized healthcare facilities, including hospitals and medical centres, contributing to the prominence of this segment.

• Many Aspergillosis cases occur in immunocompromised individuals, such as those undergoing chemotherapy or organ transplantation. These patients are at higher risk of fungal infections, including Aspergillosis, and often require hospitalization and intensive treatment. Improved diagnostic methods have enhanced the detection of Aspergillosis, leading to more accurate and timely diagnoses. This, in turn, has driven the demand for antifungal drugs for Aspergillosis treatment.

Download Free Sample Report

Regional Insights

The North India region dominated the India Anti-Fungal Drugs Market in 2024. North India boasts highly advanced healthcare infrastructure and facilities. This includes state-of-the-art hospitals, specialised orthopaedic and sports medicine clinics, and a well-developed network of healthcare providers. This infrastructure facilitates the adoption of   Anti-Fungal drug markets for various medical procedures. North India is a leader in medical technology and research. The region is home to many innovative medical device companies and biotechnology firms that have developed advanced  Anti-Fungal Drugs Market products and techniques. These technological advancements have contributed to the market's growth and dominance.

Recent Developments

• In May 2025, Cipla partnered with CSIR-Central Drug Research Institute to jointly develop a novel ophthalmic formulation for fungal keratitis, a serious corneal infection that can lead to vision loss. The companies said CSIR-CDRI had already developed a prototype anti-fungal formulation designed to improve ocular drug delivery, and pre-clinical studies indicated it could support faster resolution of infection. Under the collaboration, Cipla will scale up the product, conduct the required studies, seek regulatory approvals, and work toward commercialization, making this one of the clearest anti-fungal drug collaborations in India during 2025.

• In May 2025, researchers at IISER Thiruvananthapuram reported a breakthrough that could help shape new non-toxic anti-fungal strategies by showing that prolonged exposure to blue light damages the genetic material of budding yeast. The New Indian Express said the study linked chronic blue-light exposure to oxidative stress, DNA damage, and loss of heterozygosity in fungal cells, and researchers suggested the approach could be explored for treating drug-resistant fungal skin infections as well as for decontamination and sterilization applications. While this is not yet a marketed drug, it is a genuine India-based anti-fungal innovation story with potential downstream therapeutic relevance.

• In September 2025, researchers from IIT Madras and ICMR-NIRRCH identified ALT1, an enzyme essential to the virulence of Candida albicans, as a promising new drug target for systemic candidiasis. The report said the team used an integrated host-fungal metabolic model to uncover a hidden vulnerability in the fungus and had already validated preliminary findings in animal models, pointing toward faster and more targeted anti-fungal therapies. This qualifies as a breakthrough innovation because it opens a possible pathway to a new class of anti-fungal treatments in response to growing resistance.

• In August 2025, Glenmark Pharmaceuticals announced the upcoming launch of Micafungin for Injection USP through its US subsidiary, expanding the pipeline of India-linked anti-fungal drug manufacturing and commercialization. The company said the product, offered in 50 mg and 100 mg single-dose vials, is the therapeutic equivalent of Mycamine and would begin distribution in September 2025, reinforcing the role of Indian drugmakers in complex injectable anti-fungal products. Although the market launch was in the US, it remains relevant to India because Glenmark is an Indian pharmaceutical company and the development reflects India-origin capability in systemic anti-fungal drugs.

Key Market Players

• Pfizer India Ltd.
• Cipla Ltd.
• Glenmark Pharmaceuticals Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Viatris Inc. (Mylan NV)
• Lupin Ltd.
• Zydus Cadila Ltd.
• Novartis India Ltd.
• Abbott India Ltd.

Report Scope:

In this report, the India Anti-Fungal Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Anti-Fungal Drugs Market, By Drug Class:

o   Azoles

o   Echinocandins

o   Polyenes

o   Allylamines

o   Others

• India Anti-Fungal Drugs Market, By Indication:

o   Candidiasis

o   Aspergillosis

o   Dermatophytosis

o   Mucormycosis

o   Others

• India Anti-Fungal Drugs Market, By Infection Type:

o   Superficial Fungal Infection

o   Systemic Fungal Infection

• India Anti-Fungal Drugs Market, By Route of Administration:

o   Parenteral

o   Topical

o   Oral

o   Others

• India Anti-Fungal Drugs Market, By End-User:

o   Homecare

o   Hospitals & Clinics

o   Others

• India Anti-Fungal Drugs Market, By Distribution Channel:

o   Retail Pharmacy

o   Hospital Pharmacy

o   Online Pharmacy

• India Anti-Fungal Drugs Market, By Region:

o   North 

o   South 

o   East 

o   West 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the India Anti-Fungal Drugs Market.

Available Customizations:

India Anti-Fungal Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Anti-Fungal Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]